Quinn Nicholas J, Sebaaly Jamielynn C, Patel Bianka A, Weinrib David A, Anderson William E, Roshdy Danya G
Pharmacy Department, Atrium Health, Charlotte, NC, USA.
Pharmacy Department, Atrium Health, Charlotte, NC, USA Wingate University School of Pharmacy, Wingate, NC, USA.
Ther Adv Infect Dis. 2019 Aug 13;6:2049936119863013. doi: 10.1177/2049936119863013. eCollection 2019 Jan-Dec.
Data on the effectiveness of definitive oral (PO) antibiotics for BSIs in preparation for discharge from hospital are lacking, particularly for Gram-positive bacterial BSIs (GP-BSI). The objective of this study was to determine rates of treatment failure based on bioavailability of PO antimicrobial agents used for GP-BSI.
This was a single-center, retrospective cohort study of adult inpatients admitted to an academic medical center over a three-year period. Patients with a non-staphylococcal GP-BSI who received intravenous antibiotics and were then switched to PO antibiotics for at least a third of their treatment course were included. The cohort was stratified into high (⩾90%) and low (<90%) bioavailability groups. The primary endpoint was the proportion of patients experiencing clinical failure in each group. Secondary endpoints included clinical failure stratified by antibiotic group, bactericidal versus bacteriostatic PO agents, and organism.
A total of 103 patients met criteria for inclusion, which failed to reach the a priori power calculation. Of the patients included, 26 received high bioavailability agents and 77 received low bioavailability agents. Infections originated largely from a pulmonary source (30%) and were caused primarily by streptococcal species (75%). Treatment failure rates were 19.2% in the high bioavailability group and 23.4% in the low bioavailability group ( = 0.66). Clinical failure stratified by subgroups also did not yield statistically significant differences.
Clinical failure rates were similar among patients definitively treated with high or low bioavailability agents for GP-BSI, though the study was underpowered to detect such a difference.
关于出院时使用口服(PO)抗生素治疗血流感染(BSIs)有效性的数据,尤其是针对革兰氏阳性菌血流感染(GP-BSI)的数据尚缺。本研究的目的是根据用于治疗GP-BSI的PO抗菌药物的生物利用度来确定治疗失败率。
这是一项单中心回顾性队列研究,研究对象为在三年期间入住一所学术医疗中心的成年住院患者。纳入接受静脉抗生素治疗,随后在至少三分之一疗程中改用PO抗生素的非葡萄球菌性GP-BSI患者。该队列被分为高生物利用度组(⩾90%)和低生物利用度组(<90%)。主要终点是每组出现临床失败的患者比例。次要终点包括按抗生素组、杀菌性与抑菌性PO药物以及病原体分层的临床失败情况。
共有103例患者符合纳入标准,但未达到预先设定的样本量计算要求。在纳入的患者中,26例接受了高生物利用度药物,77例接受了低生物利用度药物。感染主要源于肺部(30%),主要由链球菌属引起(75%)。高生物利用度组的治疗失败率为19.2%,低生物利用度组为23.4%(P = 0.66)。按亚组分层的临床失败情况也未产生统计学上的显著差异。
对于GP-BSI患者,使用高生物利用度或低生物利用度药物进行最终治疗的临床失败率相似,不过该研究检测这种差异的效能不足。